BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 30317601)

  • 1. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
    Xu XL; Gong Y; Zhao DP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
    Meng F; Zhang L; Ren Y; Ma Q
    J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
    Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
    Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiomics analysis on DNA methylation and the expression of both messenger RNA and microRNA in lung adenocarcinoma.
    Yang Z; Liu B; Lin T; Zhang Y; Zhang L; Wang M
    J Cell Physiol; 2019 May; 234(5):7579-7586. PubMed ID: 30370535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Dong R; Liu J; Sun W; Ping W
    Pathol Oncol Res; 2020 Jul; 26(3):1935-1945. PubMed ID: 31898160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential
    Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcription Factors Contribute to Differential Expression in Cellular Pathways in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Liu S; Wang X; Qin W; Genchev GZ; Lu H
    Interdiscip Sci; 2018 Dec; 10(4):836-847. PubMed ID: 30039492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
    Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
    Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.
    Li H; Tong L; Tao H; Liu Z
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32031203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K; Wu Y
    BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct Patterns of mRNA and lncRNA Expression Differences Between Lung Squamous Cell Carcinoma and Adenocarcinoma.
    Tian Y; Yu M; Sun L; Liu L; Wang J; Hui K; Nan Q; Nie X; Ren Y; Ren X
    J Comput Biol; 2020 Jul; 27(7):1067-1078. PubMed ID: 31750732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
    J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Expression of
    Hu P; Huang Y; Gao Y; Yan H; Li X; Zhang J; Wang Y; Zhao Y
    DNA Cell Biol; 2020 Apr; 39(4):522-532. PubMed ID: 32040344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.